Search

Aboriginal and non-Aboriginal children in Western Australia carry different serotypes of pneumococci with different antimicrobial susceptibility profiles

Differences in pneumococcal serotypes, genotypes, and antimicrobial susceptibility between Aboriginal and non-Aboriginal children living in the same area

Rhinovirus species and clinical features in children hospitalised with pneumonia from Mozambique

The prevalence of human rhinovirus (RV) species in children hospitalised with pneumonia in Manhiça, Mozambique

A longitudinal study of natural antibody development to pneumococcal surface protein A families 1 and 2 in Papua New Guinean Highland children: a cohort study

Pneumococcal surface protein A is immunogenic and natural anti-PspA immune responses are acquired through exposure and develop with age

Respiratory viruses in young South African children with acute lower respiratory infections and interactions with HIV

RV-A and RV-C are endemic in South African children and HIV infection may be protective against RSV and bronchiolitis.

A systematic review of the evidence that swimming pools improve health and wellbeing in remote Aboriginal communities in Australia

The benefits that swimming pools may bring to to ear and eye health in remote Aboriginal communities remains unresolved

The PneuCarriage Project: A Multi-Centre Comparative Study to Identify the Best Serotyping Methods for Examining Pneumococcal Carriage

The PneuCarriage project, a large, international multi-centre study for the identification of the best pneumococcal serotyping methods for carriage studies

Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal

The impact of the 23vPPV booster on IPD incidence among Australian Indigenous children is unclear from regional reports of small case numbers.

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.

“You’re telling us to go first?!” COVID-19 pandemic and vaccination experiences among Aboriginal adults in Western Australia

Globally, Indigenous populations have been disproportionately impacted by pandemics. In Australia, though national infection rates with COVID-19 infections in Aboriginal and/or Torres Strait Islander people were lower in the first 12 months of the COVID-19 pandemic, there was soon a greater burden in Aboriginal and/or Torres Strait Island people once Omicron was circulating. Uptake of the COVID-19 vaccine was also lower among Aboriginal and/or Torres Strait Islander people.

Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules

In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.